[ RadSafe ] Ra-223 Chloride - FDA Approval

Thu May 16 18:04:55 CDT 2013

Forgive my naivete, but doesn't Ra-223 progeny Bi-211 have a gamma emission at 351 kev (12.9% intensity) as well which should be in a fair secular equilibrium with its parent. The document from the NRC seems to list only the energies directly from Ra-223 and not of its' progeny. The 269 and 154 kev gammas are directly from the Ra-223 as well as the X-Rays at 81 and 84 kev.
 What am I missing?

"223Ra and its progeny emit a number of externally countable and imageable x- and gamma-rays (81, 84, 154, and 269 keV) usable for pharmacokinetic studies, radiation dosimetry, 67 and activity calibration (7)."

Best Regards,
David

-----Original Message-----
From: Cary Renquist <cary.renquist at ezag.com>
To: The International Radiation Protection (Health Physics) MailingList <radsafe at health.phys.iit.edu>
Sent: Wed, May 15, 2013 9:11 pm
Subject: Re: [ RadSafe ] Ra-223 Chloride - FDA Approval

Here's a NRC document that gives a lot of technical info -- it appears
that that the Ra-223 is derived from Ac-227
NOTICE OF LICENSING DECISION ON RADIUM-223 DICHLORIDE (FSME-13-002)
http://nrc-stp.ornl.gov/asletters/program/sp13002.pdf
(1 MB pdf file)

---
Cary Renquist
cary.renquist at ezag.com

-----Original Message-----
From: radsafe-bounces at health.phys.iit.edu
[mailto:radsafe-bounces at health.phys.iit.edu] On Behalf Of Cary Renquist
Sent: Wednesday, 15 May 2013 5:56 PM
To: The International Radiation Protection (Health Physics) MailingList
Subject: Re: [ RadSafe ] Ra-223 Chloride - FDA Approval

I would think that there is enough Ac-227 out there to milk...

---
Cary Renquist
cary.renquist at ezag.com

-----Original Message-----
From: radsafe-bounces at health.phys.iit.edu
[mailto:radsafe-bounces at health.phys.iit.edu] On Behalf Of Brennan, Mike
(DOH)
Sent: Wednesday, 15 May 2013 4:38 PM
To: The International Radiation Protection (Health Physics) MailingList
Subject: Re: [ RadSafe ] Ra-223 Chloride - FDA Approval

There is, of course, a problem, indeed a critical problem, with
collecting up a mass of U-235 in order to milk it for Ra-223.

-----Original Message-----
From: radsafe-bounces at health.phys.iit.edu
[mailto:radsafe-bounces at health.phys.iit.edu] On Behalf Of Cary Renquist
Sent: Wednesday, May 15, 2013 3:42 PM
To: The International Radiation Protection (Health Physics) MailingList
Subject: Re: [ RadSafe ] Ra-223 Chloride - FDA Approval

Ra-223 is progeny in the U-235 decay chain...

FYI: for production mode, one of easiest sources is the LUND/LBNL Table
of Isotopes:
http://j.mp/15O1t21
e.g. For Ra-223, Prod. mode:  Naturally occurring

However, that TOI doesn't list potential "parent" nuclides...
For following decay chains, the Korea Atomic Energy Research Institute
TOI is the easiest to use...
http://j.mp/YWXP2V

---
Cary Renquist
cary.renquist at ezag.com

-----Original Message-----
From: radsafe-bounces at health.phys.iit.edu
[mailto:radsafe-bounces at health.phys.iit.edu] On Behalf Of Brennan, Mike
(DOH)
Sent: Wednesday, 15 May 2013 2:31 PM
To: The International Radiation Protection (Health Physics) MailingList
Subject: Re: [ RadSafe ] Ra-223 Chloride - FDA Approval

"The U.S. Food and Drug Administration today approved Xofigo (radium Ra
223 dichloride) to treat men with symptomatic late-stage (metastatic)
castration-resistant prostate cancer that has spread to bones but not to
other organs. It is intended for men whose cancer has spread after
receiving medical or surgical therapy to lower testosterone."

Note to self: don't get "castration-resistant prostate cancer".

How do you get Ra 223?  No path leaps out when I look at the chart of
the nuclides. 

-----Original Message-----
From: radsafe-bounces at health.phys.iit.edu
[mailto:radsafe-bounces at health.phys.iit.edu] On Behalf Of Chris Alston
Sent: Wednesday, May 15, 2013 2:03 PM
To: The International Radiation Protection (Health Physics) Mailing List
Subject: [ RadSafe ] Ra-223 Chloride - FDA Approval

Radsafers

Please see:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm352363.htm

It is hard to tell from the notice.  But I thought that this drug (did
they change the name from Alpharadin, or is that a competitor still in
IND?) was  in trials for the relief of pain from metastases to bone, and
that, incidentally, the investigators showed that pts had extensions of
life (I hope, sincerely, of decent quality, relatively speaking).  Is it
approved for the latter use, or is the FDA just saying that was why they
fast-tracked it?

Cheers
cja
_______________________________________________
You are currently subscribed to the RadSafe mailing list